VISEN Pharmaceuticals
HKSE: 2561.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- An-bang Lu
- Employees
- 58
- Headquarters
- Suzhou, China
- IPO year
- 2025
- Market cap
- HK$2.7B
- Website
- https://www.visenpharma.com/cn
Loading 2561…
Loading profile data…Frequently asked questions about 2561
What does VISEN Pharmaceuticals (2561.HK) do?
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People's Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The...
Where does 2561.HK trade?
VISEN Pharmaceuticals (2561.HK) trades on the Hong Kong Stock Exchange.
What sector is 2561.HK in?
VISEN Pharmaceuticals (2561.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of VISEN Pharmaceuticals?
An-bang Lu is the chief executive officer of VISEN Pharmaceuticals (2561.HK).
Where is VISEN Pharmaceuticals headquartered?
VISEN Pharmaceuticals is headquartered in China.
Does 2561.HK pay a dividend?
VISEN Pharmaceuticals (2561.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2561.HK go public?
VISEN Pharmaceuticals (2561.HK) completed its initial public offering in 2025.